Edwards Lifesciences Corporation: 10-Q filed 2012-11-07
What Edwards Lifesciences Corporation reported in its quarterly report filed 2012-11-07 (fiscal Q3 2012): 31 published measures, 88 facts as tagged in accession 0001047469-12-010132.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2012-11-07
- Fiscal period
- fiscal Q3 2012
- Accession
- 0001047469-12-010132 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Edwards Lifesciences Corporation filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 2,195,800,000 | USD | |
| At 2011-12-31 | 1,980,500,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 1,536,300,000 | USD | |
| At 2011-12-31 | 1,337,900,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 305,800,000 | USD | |
| At 2011-12-31 | 171,200,000 | USD | |
| At 2011-09-30 | 244,000,000 | USD | |
| At 2010-12-31 | 396,100,000 | USD |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | 64,900,000 | USD | 274 |
| 2011-01-01 to 2011-09-30 | 50,600,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 1,562,800,000 | USD | |
| At 2011-12-31 | 1,360,700,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 115,700,000 | shares | 92 |
| 2012-01-01 to 2012-09-30 | 114,900,000 | shares | 274 |
| 2011-07-01 to 2011-09-30 | 114,600,000 | shares | 92 |
| 2011-01-01 to 2011-09-30 | 114,800,000 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 119,000,000 | shares | 92 |
| 2012-01-01 to 2012-09-30 | 118,400,000 | shares | 274 |
| 2011-07-01 to 2011-09-30 | 119,000,000 | shares | 92 |
| 2011-01-01 to 2011-09-30 | 119,800,000 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 0.6 | USD/shares | 92 |
| 2012-01-01 to 2012-09-30 | 1.76 | USD/shares | 274 |
| 2011-07-01 to 2011-09-30 | 0.45 | USD/shares | 92 |
| 2011-01-01 to 2011-09-30 | 1.51 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 0.58 | USD/shares | 92 |
| 2012-01-01 to 2012-09-30 | 1.71 | USD/shares | 274 |
| 2011-07-01 to 2011-09-30 | 0.43 | USD/shares | 92 |
| 2011-01-01 to 2011-09-30 | 1.45 | USD/shares | 273 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 24,200,000 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 66,800,000 | USD | 274 |
| 2011-07-01 to 2011-09-30 | 6,000,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 41,400,000 | USD | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 328,700,000 | USD | |
| At 2011-12-31 | 304,300,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | 31,300,000 | USD | 274 |
| 2011-01-01 to 2011-09-30 | 26,000,000 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 1,387,700,000 | USD | |
| At 2011-12-31 | 1,168,500,000 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 349,800,000 | USD | |
| At 2011-12-31 | 349,800,000 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 53,300,000 | USD | |
| At 2011-12-31 | 60,600,000 | USD |
Common-stock repurchase payments
Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | 166,300,000 | USD | 274 |
| 2011-01-01 to 2011-09-30 | 263,300,000 | USD | 273 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 286,000,000 | USD | |
| At 2011-12-31 | 261,300,000 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 336,200,000 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 1,020,300,000 | USD | 274 |
| 2011-07-01 to 2011-09-30 | 287,100,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 878,200,000 | USD | 273 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 167,800,000 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 527,400,000 | USD | 274 |
| 2011-07-01 to 2011-09-30 | 165,500,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 479,000,000 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 73,800,000 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 216,400,000 | USD | 274 |
| 2011-07-01 to 2011-09-30 | 61,700,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 185,600,000 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 116,000,000 | shares | |
| At 2011-12-31 | 114,100,000 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | -37,100,000 | USD | |
| At 2011-12-31 | -37,500,000 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 59,600,000 | USD | |
| At 2011-12-31 | 66,900,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 26,000,000 | USD | |
| At 2011-12-31 | 24,600,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 185,500,000 | USD | |
| At 2011-12-31 | 157,000,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 83,100,000 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 202,500,000 | USD | 274 |
| 2011-07-01 to 2011-09-30 | 37,900,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 192,500,000 | USD | 273 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 69,200,000 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 202,100,000 | USD | 274 |
| 2011-07-01 to 2011-09-30 | 51,600,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 173,600,000 | USD | 273 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | 42,200,000 | USD | 274 |
| 2011-01-01 to 2011-09-30 | 43,200,000 | USD | 273 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 3,500,000 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 10,100,000 | USD | 274 |
| 2011-07-01 to 2011-09-30 | 2,400,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 10,800,000 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | -1,500,000 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -1,000,000 | USD | 274 |
| 2011-07-01 to 2011-09-30 | -2,300,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 5,100,000 | USD | 273 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | 23,900,000 | USD | 274 |
| 2011-01-01 to 2011-09-30 | 38,300,000 | USD | 273 |
Inspect the source
- Entity
- Edwards Lifesciences Corporation / CIK 0001099800
- Captured
- 2026-09-20T05:22:59.752Z
- SEC response SHA-256
5e8f751fbec9a0a1ff653c4d2070ea46d6cde3f7ccf35f9c1d7367a126bc76c1
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001099800.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))